Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will post earnings per share (EPS) of ($0.63) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Gene Therapies earnings, with estimates ranging from ($0.66) to ($0.57). Axovant Gene Therapies reported earnings of ($2.16) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 70.8%. The business is expected to report its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that Axovant Gene Therapies will report full year earnings of ($3.56) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($1.84). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.32) per share, with EPS estimates ranging from ($2.84) to ($1.20). Zacks Investment Researchs earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its earnings results on Friday, November 8th. The company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($1.15) by $0.54.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 target price on the stock in a report on Wednesday, November 13th. ValuEngine upgraded shares of Axovant Gene Therapies from a hold rating to a buy rating in a report on Friday. Finally, Chardan Capital raised their price objective on shares of Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a buy rating in a report on Monday, October 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $24.72.

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC acquired a new stake in shares of Axovant Gene Therapies during the third quarter worth $65,000. Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies during the second quarter worth $1,482,000. Institutional investors and hedge funds own 14.80% of the companys stock.

AXGT opened at $4.95 on Tuesday. The firms fifty day moving average is $5.18 and its two-hundred day moving average is $6.20. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.69. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
-$0.63 Earnings Per Share Expected for Axovant Gene Therapies Ltd (NASDAQ:AXGT) This Quarter - Riverton Roll

Comments are closed.